These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 24259738

  • 1. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
    Baruch L, Sherman O.
    Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
    [Abstract] [Full Text] [Related]

  • 2. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L, Sherman O.
    Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
    [Abstract] [Full Text] [Related]

  • 3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.
    J Am Coll Cardiol; 2013 Feb 12; 61(6):651-8. PubMed ID: 23391196
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W.
    Ann Intern Med; 2013 Jun 18; 158(12):861-8. PubMed ID: 23778903
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM, ROCKET AF Steering Committee and Investigators.
    Circulation; 2013 Jan 15; 127(2):224-32. PubMed ID: 23212720
    [Abstract] [Full Text] [Related]

  • 10. Oral rivaroxaban for symptomatic venous thromboembolism.
    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.
    N Engl J Med; 2010 Dec 23; 363(26):2499-510. PubMed ID: 21128814
    [Abstract] [Full Text] [Related]

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
    Adv Ther; 2012 Jun 23; 29(6):491-507. PubMed ID: 22684583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients.
    Lawrie AS, Hills J, Longair I, Green L, Gardiner C, Machin SJ, Cohen H.
    Thromb Res; 2012 Jul 23; 130(1):110-4. PubMed ID: 21937093
    [Abstract] [Full Text] [Related]

  • 14. International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing.
    Bonar R, Mohammed S, Favaloro EJ.
    Semin Thromb Hemost; 2015 Apr 23; 41(3):279-86. PubMed ID: 25839866
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.
    Am J Cardiol; 2012 Sep 15; 110(6):845-51. PubMed ID: 22651881
    [Abstract] [Full Text] [Related]

  • 16. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS, Manolakos JJ, Eikelboom JW.
    Expert Rev Cardiovasc Ther; 2012 Aug 15; 10(8):965-72. PubMed ID: 23030284
    [Abstract] [Full Text] [Related]

  • 17. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
    Simonyi G, Medvegy M.
    Ideggyogy Sz; 2012 Nov 30; 65(11-12):365-8. PubMed ID: 23289170
    [Abstract] [Full Text] [Related]

  • 18. Performance of a point-of-care device in determining prothrombin time in supra-therapeutic INRs.
    Hashimoto VA, De Paula EV, Colella MP, Luz Fiusa MM, Montalvao SA, Machado TF, Orsi FA, Annichino-Bizzacchi JM.
    Int J Lab Hematol; 2013 Apr 30; 35(2):211-6. PubMed ID: 23173728
    [Abstract] [Full Text] [Related]

  • 19. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators.
    Circulation; 2007 Jul 10; 116(2):180-7. PubMed ID: 17576867
    [Abstract] [Full Text] [Related]

  • 20. Accuracy of point of care coagulometers compared to reference laboratory measurements in patients on oral anticoagulation therapy.
    Dillinger JG, Si Moussi T, Berge N, Bal Dit Sollier C, Henry P, Drouet L.
    Thromb Res; 2016 Apr 10; 140():66-72. PubMed ID: 26901852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.